May 23 Financial Quick Takes: NYSE to lower fees for biotechs; plus Guardant and more

NYSE proposes lower fees for prerevenue biotechs
For biotech companies with a market cap of at least $200 million and annual revenues of $5 million or less,

Read the full 260 word article

User Sign In